

Title (en)
NOVEL SPIROQUINONE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS WHICH CONTAINS SAME AS ACTIVE INGREDIENT

Title (de)
NEUARTIGE SPIROCHINONDERIVATVERBINDUNG, HERSTELLUNGSVERFAHREN DAFÜR UND PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT ALS WIRKSTOFF ZUR VORBEUGUNG ODER BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN

Title (fr)
NOUVEAU COMPOSÉ DÉRIVÉ DE SPIROQUINONE, SON PROCÉDÉ DE PRODUCTION, ET COMPOSITION PHARMACEUTIQUE LE CONTENANT EN TANT QUE PRINCIPE ACTIF POUR PRÉVENIR OU TRAITER DES TROUBLES NEUROLOGIQUES

Publication
EP 3395804 A4 20190320 (EN)

Application
EP 17849145 A 20170908

Priority
• KR 20160115468 A 20160908
• KR 2017009909 W 20170908

Abstract (en)
[origin: EP3395804A1] The present invention relates to a novel spiroquinone derivative compound, a production method thereof, and a pharmaceutical composition for preventing or treating neurological disorders which contains the compound as an active ingredient, and it has been confirmed that the novel spiroquinone derivative compound according to the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof may excellently suppress 'microglial activation' and shows excellent inhibition activity against acetylcholinesterase, JNK1, JNK2 and JNK3, and in addition to this, significant enzyme inhibition activity has been confirmed in a neurological diseases-related enzyme group, RIPK5, CDK3/cyclin E, PKN2/PRK2, Haspin, STK25/YSK1, ARK5/NUAK1, PKCb2, CDK2/cyclin O, DAPK1, PKCa, CDK1/cyclin B, MST3/STK24 and TLK1 and it has been confirmed that cell death suppression effect may be exhibited, and thus the novel spiroquinone derivative compound according to the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof can be usefully used for a pharmaceutical composition for preventing or treating neurological disorders or health functional food composition for preventing or improving neurological disorders by being contained therein as an active ingredient.

IPC 8 full level
C07D 265/14 (2006.01); **A23L 33/10** (2016.01); **A61K 31/537** (2006.01); **C07C 235/16** (2006.01); **C07C 235/28** (2006.01); **C07C 235/38** (2006.01); **C07C 255/57** (2006.01); **C07C 317/46** (2006.01)

CPC (source: EP KR US)
A23L 33/10 (2016.07 - EP KR US); **A61K 31/537** (2013.01 - EP KR US); **A61P 25/28** (2017.12 - EP US); **C07C 235/16** (2013.01 - EP US); **C07C 235/28** (2013.01 - EP US); **C07C 235/38** (2013.01 - EP US); **C07C 255/57** (2013.01 - EP US); **C07C 317/46** (2013.01 - EP US); **C07D 213/75** (2013.01 - EP US); **C07D 265/14** (2013.01 - EP KR US); **C07D 265/22** (2013.01 - EP US); **C07D 413/04** (2013.01 - EP US); **C07D 413/06** (2013.01 - EP US); **A23V 2002/00** (2013.01 - KR); **A23V 2200/322** (2013.01 - KR)

Citation (search report)
• [A] WO 2008129007 A1 20081030 - GLAXO GROUP LTD [GB], et al
• See references of WO 2018048261A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
EP 3395804 A1 20181031; **EP 3395804 A4 20190320**; **EP 3395804 B1 20200513**; CN 108699013 A 20181023; CN 108699013 B 20220506; KR 101850062 B1 20180419; KR 20180028391 A 20180316; US 10836734 B2 20201117; US 2018327370 A1 20181115; WO 2018048261 A1 20180315

DOCDB simple family (application)
EP 17849145 A 20170908; CN 201780013645 A 20170908; KR 2017009909 W 20170908; KR 20170115445 A 20170908; US 201816044285 A 20180724